Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Taurus Asset Management LLC

Taurus Asset Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,041 shares of the biopharmaceutical company’s stock after buying an additional 134 shares during the period. Regeneron Pharmaceuticals accounts for 1.7% of Taurus Asset Management LLC’s holdings, making the stock its 27th biggest position. Taurus Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $16,859,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $932,571,000. Global Assets Advisory LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $339,594,000. Capital International Investors lifted its holdings in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. First Trust Advisors LP lifted its holdings in Regeneron Pharmaceuticals by 115.2% during the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after purchasing an additional 195,902 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Truist Financial restated a “buy” rating and issued a $1,200.00 target price (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. Piper Sandler boosted their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, September 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,109.70.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the sale, the director now owns 1,382 shares in the company, valued at approximately $1,467,684. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,026 shares of company stock worth $11,498,705. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.0 %

REGN stock opened at $1,153.35 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The firm has a market cap of $127.15 billion, a PE ratio of 34.07, a PEG ratio of 3.89 and a beta of 0.12. The firm’s 50 day moving average price is $1,124.22 and its 200-day moving average price is $1,026.18. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.79 earnings per share. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.